Gabapentin Tablet
Product Images NDC 60760-743

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 60760-743). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by St. Mary's Medical Park Pharmacy, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Gab (Gabapentin 60760 743 90)

This is a description of Gabapentin, a medication that comes in the form of tablets with a strength of 600mg. It is available in a quantity of 90 tablets per bottle, and each tablet is manufactured by ScienGen Pharmaceuticals, Inc. The medication is prescribed with an RX number and National Drug Code (NDC) for dispensing by pharmacies. The recommended use is as directed by a physician, and it should be stored at a controlled room temperature. The expiration, lot number, and other related details of the medication are also given.*

FDA Label Image

Figure 1 (Image 01)

The text mentions mean pain score and two types of dosages, work dose titration and fixed dose period, along with a placebo and Gabapentin at 3600 mg/day. The data is also organized in a table with information for baseline and weeks. There is not enough context to determine the purpose or context of the text.*

FDA Label Image

Figure 2 (Image 02)

This is a graph displaying the mean pain score for different doses of Gabapentin and Placebo over a period of 7 weeks. The dose of Gabapentin is either 1800 or 2400 mg per day. The X-axis represents the weeks of the study, and the Y-axis represents the mean pain score.*

FDA Label Image

Figure 3 (Image 03)

FDA Label Image

Image-04 (Image 04)

FDA Label Image

Gabapentin Structural Formula (Image 05)

FDA Label Image

Figure 4. Responder Rate In Patients Receiving Gabapentin Expressed As A Difference From Placebo By Dose And Study: Adjunctive Therapy Studies In Patients ≥12 Years Of Age With Partial Seizures (Image 09)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.